
The most selective and clean GHRP — stimulates GH without raising cortisol, prolactin, or appetite. Individual high-concentration presentation.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Ipamorelin is a synthetic pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — designed by Novo Nordisk and described in 1998 (Raun et al., European Journal of Endocrinology). It belongs to the family of GH secretagogues: molecules that mimic ghrelin at its GHSR-1a receptor in the pituitary and hypothalamus. It contains two non-natural amino acids (aminoisobutyric acid and D-2-naphthylalanine) that shield it from peptidases and give it a half-life of around two hours.
What set it apart from the first study was selectivity. GHRP-6 and GHRP-2, the earlier secretagogues, release GH but also ACTH, cortisol and prolactin; ipamorelin, at GH-releasing concentrations, did not alter those hormones in animal models or in the initial human studies, and it does not stimulate appetite the way GHRP-6 does. That is why it is described as the “clean” secretagogue and is the one usually paired with GHRH analogs in research.
Its later clinical development targeted postoperative ileus, exploiting the prokinetic action of ghrelin agonists; Helsinn took it to Phase 2 and the program closed in 2014 without meeting its endpoints, so it never obtained approval. Human data on body composition or aging are scarce. Like every secretagogue it raises GH and IGF-1 and is on the World Anti-Doping Agency list. Renova distributes it for research only.
| Class | GH secretagogue, selective ghrelin-receptor (GHSR-1a) agonist |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide with 2 non-natural amino acids) |
| CAS | 170851-70-4 |
| Origin | Novo Nordisk; Raun et al., 1998 |
| Half-life | ≈ 2 hours |
| Selectivity | No significant rise in ACTH, cortisol or prolactin at GH-releasing concentrations |
| Clinical development | Phase 2 in postoperative ileus (Helsinn), closed 2014; not approved |
| Regulatory status | WADA list (S2); Renova presentations: 10 mg vial and blend with CJC-1295 |
In Novo Nordisk's studies, at GH-releasing doses it did not raise ACTH, cortisol or prolactin, whereas GHRP-6 and GHRP-2 do. Nor does it cause the marked appetite increase typical of GHRP-6. The difference lies in how each molecule interacts with the ghrelin receptor and with other systems.
Aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2-Nal) do not occur in natural proteins; they were built in to block peptidases and hold the active shape. They are the reason a five-residue peptide lasts about two hours in circulation instead of minutes.
Yes, but not for GH: Helsinn studied it intravenously in postoperative ileus (recovery of gut motility after abdominal surgery), exploiting the fact that ghrelin agonists are prokinetic. The Phase 2 program closed in 2014 without meeting its endpoints and the molecule was not approved.
The individual vial allows studying the secretagogue alone or adjusting the ratio with a GHRH analog. The CJC-1295 / Ipamorelin blend fixes a 1:1 ratio and simplifies reconstitution. The stack guide explains the synergy between the two classes.
Related reading: CJC-1295 + Ipamorelin: The Most-Studied GH Stack · GHRP-6: GH Secretagogue and Ghrelin
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty